Obesity GLP-1 Market

Future Market Insights

Obesity GLP-1 Market

Key Insight

The obesity GLP-1 market is projected to grow from USD 8169.0 million in 2025 to USD 65,364 million by 2035, advancing at a CAGR of 23.1%. Semaglutide is expected to lead the market with a 58% share in 2025, while private and self-pay arrangements are anticipated to account for 70% of the payer segment.

October 14, 2025

Anurag Sharma

250 Pages

Cite this Report

Obesity GLP-1 Market

https://www.futuremarketinsights.com/reports/obesity-glp-1-market

License

Buy Now

Summary ToC Companies

Key Players

Amgen
BlackRock
BoehringerIngelheim
Eli Lilly and Company
Novo Nordisk A/S
The Vanguard Group
Roche
Structure Therapeutics
Viking Therapeutics
Zealand Pharma A/S

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Obesity GLP-1 Market

Key Players

Similar Industry Reports